Clinical trials: MSS Metastatic Colorectal Cancer
Colorectal Cancer
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
This study is evaluating the combination of Y-90 radioembolization followed by SBRT with the immunotherapy drugs, durvalumab and tremelimumab, to improve disease control of liver metastases for patients with microsatellite stable…
- Trial name
- NCT03802747
- Testing
- Durvalumab, Durvalumab and Tremelimumab, Y-90 Selective Internal Radiation Therapy (SIRT)
- Sponsor
- University of Colorado, Denver
Colorectal Cancer Metastatic
BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases
The goal of this clinical trial is to learn whether the combination of balstilimab, botensilimab, and agenT-797 is safe and effective in treating adults with previously treated metastatic colorectal cancer that is microsatellite…
- Trial name
- NCT07550088
- Testing
- Balstilimab (BAL), Botensilimab (BOT), agenT-797
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Darren Sigal, MD
Tislelizumab, Bevacizumab
XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
The goal of this clinical trial is to compare XELOX +Bev +Tislelizumab with standard chemotherapy，in MSS/pMMR-type RAS-mutated metastatic colorectal adenocarcinoma.
- Conditions
- Tislelizumab, Bevacizumab, Oxaliplatin, Capecitabine
- Trial name
- NCT05970302
- Testing
- Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
This is an open-label, single-arm, single-center phase II clinical study, aiming to investigate the safety and efficacy of Aipalolitovorelizumab (QL1706) combined with bevacizumab plus standard chemotherapy regimen as first-line…
- Trial name
- NCT07229846
- Testing
- Aipalolitovorelizumab, XELOX + Bevacizumab, mFOLFOX + Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yanqiao Zhang
Colorectal Cancer Metastatic
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
The prognosis of most patients with unresectable locally advanced or metastatic colorectal cancer (CRC) remains poor despite the advancements in chemotherapy and target therapy.
- Trial name
- NCT06685276
- Testing
- Fruquintinib, Sintilimab, Chidamide
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Dai, Guanghai
Metastatic Microsatellite-stable Colorectal Cancer
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
COLUMBIA-1 is a Phase 1b/2 platform study to evaluate the safety and efficacy of standard of care (FOLFOX plus bevacizumab) alone and in combination with novel oncology therapies in first-line metastatic microsatellite-stable…
- Trial name
- NCT04068610
- Testing
- Durvalumab, Oleclumab, FOLFOX
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 61 people
- Sponsor
- MedImmune LLC
Metastatic Colorectal Cancer, Liver Metastases
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
This Phase 1b/2 trial will evaluate the safety and efficacy of neoadjuvant immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) subjects with resectable liver metastases.
- Trial name
- NCT07277322
- Testing
- Dupilumab, Toripalimab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Dan Feng
Mismatch Repair-proficient, Colorectal Cancer Metastatic
Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer
Explore the efficacy of radiotherapy combined with Tislelizumab and irinotecan in MSS/pMMR inoperable recurrent and metastatic colorectal cancer patients; To evaluate the safety and tolerability of radiotherapy combined with…
- Conditions
- Mismatch Repair-proficient, Colorectal Cancer Metastatic, Microsatellite Stable
- Trial name
- NCT05160727
- Testing
- Tislelizumab, Irinotecan, radiotherapy
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Colorectal Cancer, MSS
Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab
Fluorouracil and oxaliplatin-based combined with molecular targeted drugs are still the main treatment strategies for patients with advanced metastatic colorectal cancer (mCRC).
- Trial name
- NCT06415851
- Testing
- mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhangfa Song
RAS Mutation, Metastatic Colorectal Cancer
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
This is a non-profit phase II, open, clinical study of the combination of irinotecan plus cetuximab and envafolimab as a rechallenge regimen, in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients (according to…
- Conditions
- RAS Mutation, Metastatic Colorectal Cancer, MSS
- Trial name
- NCT06321081
- Testing
- irinotecan, cetuximab, envafolimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Hospital